Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 601 to 609 of 609 entries
Sorted by: Best Match Show Resources per page
Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19.

iScience

Bell LCK, Meydan C, Kim J, Foox J, Butler D, Mason CE, Shapira SD, Noursadeghi M, Pollara G.
PMID: 33319166
iScience. 2021 Jan 22;24(1):101896. doi: 10.1016/j.isci.2020.101896. Epub 2020 Dec 07.

Dysregulated IL-1β and IL-6 responses have been implicated in the pathogenesis of severe Coronavirus Disease 2019 (COVID-19). Innovative approaches for evaluating the biological activity of these cytokines

Cite
Bell LCK, Meydan C, Kim J, et al. Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience. 2020;24(1):101896doi: 10.1016/j.isci.2020.101896.
Bell, L. C. K., Meydan, C., Kim, J., Foox, J., Butler, D., Mason, C. E., Shapira, S. D., Noursadeghi, M., & Pollara, G. (2021). Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience, 24(1), 101896. https://doi.org/10.1016/j.isci.2020.101896
Bell, Lucy C K, et al. "Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19." iScience vol. 24,1 (2021): 101896. doi: https://doi.org/10.1016/j.isci.2020.101896
Bell LCK, Meydan C, Kim J, Foox J, Butler D, Mason CE, Shapira SD, Noursadeghi M, Pollara G. Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience. 2021 Jan 22;24(1):101896. doi: 10.1016/j.isci.2020.101896. Epub 2020 Dec 07. PMID: 33319166; PMCID: PMC7721347.
Copy Download .nbib Format: NLM
Case report: A case of Norrie disease due to deletion of the entire coding region of .

American journal of ophthalmology case reports

Zhou Y, Shapiro MJ, Burton BK, Mets MB, Kurup SP.
PMID: 34189345
Am J Ophthalmol Case Rep. 2021 Jun 17;23:101151. doi: 10.1016/j.ajoc.2021.101151. eCollection 2021 Sep.

PURPOSE: Norrie disease is a rare X-linked recessive vitreoretinopathy. Variants of the OBSERVATIONS: A retrospective chart review of the patient's ocular and systemic findings and imaging results was performed. The patient had received genetic testing, including mutational analysis of...

Cite
Zhou Y, Shapiro MJ, Burton BK, et al. Case report: A case of Norrie disease due to deletion of the entire coding region of . Am J Ophthalmol Case Rep. 2021;23:101151doi: 10.1016/j.ajoc.2021.101151.
Zhou, Y., Shapiro, M. J., Burton, B. K., Mets, M. B., & Kurup, S. P. (2021). Case report: A case of Norrie disease due to deletion of the entire coding region of . American journal of ophthalmology case reports, 23101151. https://doi.org/10.1016/j.ajoc.2021.101151
Zhou, Yujia, et al. "Case report: A case of Norrie disease due to deletion of the entire coding region of ." American journal of ophthalmology case reports vol. 23 (2021): 101151. doi: https://doi.org/10.1016/j.ajoc.2021.101151
Zhou Y, Shapiro MJ, Burton BK, Mets MB, Kurup SP. Case report: A case of Norrie disease due to deletion of the entire coding region of . Am J Ophthalmol Case Rep. 2021 Jun 17;23:101151. doi: 10.1016/j.ajoc.2021.101151. eCollection 2021 Sep. PMID: 34189345; PMCID: PMC8220341.
Copy Download .nbib Format: NLM
Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study.

Circulation

Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez Sendon JL, Senior R, El-Hajjar MC, Celutkiene J, Shapiro MD, Pellikka PA, Kunichoff DF, Anthopolos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JK, Fleg JL, Li Y, Maron DJ, Hochman JS.
PMID: 34058845
Circulation. 2021 Sep 28;144(13):1008-1023. doi: 10.1161/CIRCULATIONAHA.120.046791. Epub 2021 Jun 01.

BACKGROUND: Ischemia with no obstructive coronary artery disease (INOCA) is common and has an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in INOCA.METHODS: CIAO-ISCHEMIA (Changes in Ischemia and Angina over One Year...

Cite
Reynolds HR, Picard MH, Spertus JA, et al. Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. Circulation. 2021;144(13):1008-1023doi: 10.1161/CIRCULATIONAHA.120.046791.
Reynolds, H. R., Picard, M. H., Spertus, J. A., Peteiro, J., Lopez Sendon, J. L., Senior, R., El-Hajjar, M. C., Celutkiene, J., Shapiro, M. D., Pellikka, P. A., Kunichoff, D. F., Anthopolos, R., Alfakih, K., Abdul-Nour, K., Khouri, M., Bershtein, L., De Belder, M., Poh, K. K., Beltrame, J. F., Min, J. K., Fleg, J. L., Li, Y., Maron, D. J., & Hochman, J. S. (2021). Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. Circulation, 144(13), 1008-1023. https://doi.org/10.1161/CIRCULATIONAHA.120.046791
Reynolds, Harmony R, et al. "Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study." Circulation vol. 144,13 (2021): 1008-1023. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.046791
Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez Sendon JL, Senior R, El-Hajjar MC, Celutkiene J, Shapiro MD, Pellikka PA, Kunichoff DF, Anthopolos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JK, Fleg JL, Li Y, Maron DJ, Hochman JS. Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. Circulation. 2021 Sep 28;144(13):1008-1023. doi: 10.1161/CIRCULATIONAHA.120.046791. Epub 2021 Jun 01. PMID: 34058845; PMCID: PMC8478858.
Copy Download .nbib Format: NLM
Genetically encodable materials for non-invasive biological imaging.

Nature materials

Farhadi A, Sigmund F, Westmeyer GG, Shapiro MG.
PMID: 33526879
Nat Mater. 2021 May;20(5):585-592. doi: 10.1038/s41563-020-00883-3. Epub 2021 Feb 01.

Many questions in basic biology and medicine require the ability to visualize the function of specific cells and molecules inside living organisms. In this context, technologies such as ultrasound, optoacoustics and magnetic resonance provide non-invasive imaging access to deep-tissue...

Cite
Farhadi A, Sigmund F, Westmeyer GG, et al. Genetically encodable materials for non-invasive biological imaging. Nat Mater. 2021;20(5):585-592doi: 10.1038/s41563-020-00883-3.
Farhadi, A., Sigmund, F., Westmeyer, G. G., & Shapiro, M. G. (2021). Genetically encodable materials for non-invasive biological imaging. Nature materials, 20(5), 585-592. https://doi.org/10.1038/s41563-020-00883-3
Farhadi, Arash, et al. "Genetically encodable materials for non-invasive biological imaging." Nature materials vol. 20,5 (2021): 585-592. doi: https://doi.org/10.1038/s41563-020-00883-3
Farhadi A, Sigmund F, Westmeyer GG, Shapiro MG. Genetically encodable materials for non-invasive biological imaging. Nat Mater. 2021 May;20(5):585-592. doi: 10.1038/s41563-020-00883-3. Epub 2021 Feb 01. PMID: 33526879; PMCID: PMC8606175.
Copy Download .nbib Format: NLM
Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart.

JACC. CardioOncology

Shapira-Daniels A, Katz D, Aviel G, Meirovitz A, Gilon D, Shapira OM.
PMID: 34396262
JACC CardioOncol. 2020 Sep 15;2(3):519-522. doi: 10.1016/j.jaccao.2020.06.008. eCollection 2020 Sep.

No abstract available.

Cite
Shapira-Daniels A, Katz D, Aviel G, et al. Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart. JACC CardioOncol. 2020;2(3):519-522doi: 10.1016/j.jaccao.2020.06.008.
Shapira-Daniels, A., Katz, D., Aviel, G., Meirovitz, A., Gilon, D., & Shapira, O. M. (2020). Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart. JACC. CardioOncology, 2(3), 519-522. https://doi.org/10.1016/j.jaccao.2020.06.008
Shapira-Daniels, Ayelet, et al. "Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart." JACC. CardioOncology vol. 2,3 (2020): 519-522. doi: https://doi.org/10.1016/j.jaccao.2020.06.008
Shapira-Daniels A, Katz D, Aviel G, Meirovitz A, Gilon D, Shapira OM. Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart. JACC CardioOncol. 2020 Sep 15;2(3):519-522. doi: 10.1016/j.jaccao.2020.06.008. eCollection 2020 Sep. PMID: 34396262; PMCID: PMC8352254.
Copy Download .nbib Format: NLM
Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk.

European journal of preventive cardiology

German CA, Shapiro MD.
PMID: 33961017
Eur J Prev Cardiol. 2022 Jan 11;28(16):1817-1818. doi: 10.1093/eurjpc/zwab057.

No abstract available.

Cite
German CA, Shapiro MD. Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk. Eur J Prev Cardiol. 2022;28(16):1817-1818doi: 10.1093/eurjpc/zwab057.
German, C. A., & Shapiro, M. D. (2022). Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk. European journal of preventive cardiology, 28(16), 1817-1818. https://doi.org/10.1093/eurjpc/zwab057
German, Charles Amir, and Shapiro, Michael David. "Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk." European journal of preventive cardiology vol. 28,16 (2022): 1817-1818. doi: https://doi.org/10.1093/eurjpc/zwab057
German CA, Shapiro MD. Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk. Eur J Prev Cardiol. 2022 Jan 11;28(16):1817-1818. doi: 10.1093/eurjpc/zwab057. PMID: 33961017.
Copy Download .nbib Format: NLM
Severe aortic stenosis echocardiographic thresholds revisited.

Echocardiography (Mount Kisco, N.Y.)

Schwartzenberg S, Vatury M, Wiessman M, Shechter A, Morelli O, Ofek H, Kazum S, Kornowski R, Sagie A, Shapira Y.
PMID: 34854128
Echocardiography. 2021 Dec;38(12):2016-2024. doi: 10.1111/echo.15241. Epub 2021 Dec 01.

BACKGROUND: In view of inconsistencies in threshold values of severe aortic stenosis (AS) hemodynamic indices, it is unclear what is the relative contribution of each variable in a binary classification of AS based on aortic valve replacement (AVR) indication....

Cite
Schwartzenberg S, Vatury M, Wiessman M, et al. Severe aortic stenosis echocardiographic thresholds revisited. Echocardiography. 2021;38(12):2016-2024doi: 10.1111/echo.15241.
Schwartzenberg, S., Vatury, M., Wiessman, M., Shechter, A., Morelli, O., Ofek, H., Kazum, S., Kornowski, R., Sagie, A., & Shapira, Y. (2021). Severe aortic stenosis echocardiographic thresholds revisited. Echocardiography (Mount Kisco, N.Y.), 38(12), 2016-2024. https://doi.org/10.1111/echo.15241
Schwartzenberg, Shmuel, et al. "Severe aortic stenosis echocardiographic thresholds revisited." Echocardiography (Mount Kisco, N.Y.) vol. 38,12 (2021): 2016-2024. doi: https://doi.org/10.1111/echo.15241
Schwartzenberg S, Vatury M, Wiessman M, Shechter A, Morelli O, Ofek H, Kazum S, Kornowski R, Sagie A, Shapira Y. Severe aortic stenosis echocardiographic thresholds revisited. Echocardiography. 2021 Dec;38(12):2016-2024. doi: 10.1111/echo.15241. Epub 2021 Dec 01. PMID: 34854128.
Copy Download .nbib Format: NLM
Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome.

medRxiv : the preprint server for health sciences

Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, May B, De Freitas JK, Glicksberg BS, Mason CE, Tatonetti NP, Shapira SD.
PMID: 32511494
medRxiv. 2020 Jun 06; doi: 10.1101/2020.05.05.20092452.

Understanding the pathophysiology of SARS-CoV-2 infection is critical for therapeutics and public health intervention strategies. Viral-host interactions can guide discovery of regulators of disease outcomes, and protein structure function analysis points to several immune pathways, including complement and coagulation,...

Cite
Ramlall V, Thangaraj PM, Meydan C, et al. Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv. 2020;doi: 10.1101/2020.05.05.20092452.
Ramlall, V., Thangaraj, P. M., Meydan, C., Foox, J., Butler, D., May, B., De Freitas, J. K., Glicksberg, B. S., Mason, C. E., Tatonetti, N. P., & Shapira, S. D. (2020). Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.05.05.20092452
Ramlall, Vijendra, et al. "Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.05.05.20092452
Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, May B, De Freitas JK, Glicksberg BS, Mason CE, Tatonetti NP, Shapira SD. Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv. 2020 Jun 06; doi: 10.1101/2020.05.05.20092452. PMID: 32511494; PMCID: PMC7273262.
Copy Download .nbib Format: NLM
Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race.

JCO oncology practice

Frosch ZAK, Namoglu EC, Mitra N, Landsburg DJ, Nasta SD, Bekelman JE, Iyengar R, Guerra CE, Schapira MM.
PMID: 34524837
JCO Oncol Pract. 2022 Jan;18(1):e193-e203. doi: 10.1200/OP.21.00312. Epub 2021 Sep 15.

PURPOSE: Patients weigh competing priorities when deciding whether to travel to a cellular therapy center for treatment. We conducted a choice-based conjoint analysis to determine the relative value they place on clinical factors, oncologist continuity, and travel time under...

Cite
Frosch ZAK, Namoglu EC, Mitra N, et al. Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO Oncol Pract. 2021;18(1):e193-e203doi: 10.1200/OP.21.00312.
Frosch, Z. A. K., Namoglu, E. C., Mitra, N., Landsburg, D. J., Nasta, S. D., Bekelman, J. E., Iyengar, R., Guerra, C. E., & Schapira, M. M. (2022). Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO oncology practice, 18(1), e193-e203. https://doi.org/10.1200/OP.21.00312
Frosch, Zachary A K, et al. "Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race." JCO oncology practice vol. 18,1 (2022): e193-e203. doi: https://doi.org/10.1200/OP.21.00312
Frosch ZAK, Namoglu EC, Mitra N, Landsburg DJ, Nasta SD, Bekelman JE, Iyengar R, Guerra CE, Schapira MM. Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO Oncol Pract. 2022 Jan;18(1):e193-e203. doi: 10.1200/OP.21.00312. Epub 2021 Sep 15. PMID: 34524837; PMCID: PMC8757965.
Copy Download .nbib Format: NLM
Showing 601 to 609 of 609 entries